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ABSTRAK 
 
Pendahuluan: Rawatan menggunakan radioaktif Iodin-131 merupakan satu kaedah yang 
terbukti kegunaannya dalam rawatan penyakit kelenjar tiroid termasuklah penyakit bukan 
barah tiroid yang berkaitan hipertiroid dan juga penyakit kanser tiroid. Persediaan 
merangkumi amalan pemakanan diet sekatan iodin sebelum menjalani rawatan untuk 
menghasilkan keadaan kekurangan zat iodin dalam tubuh adalah penting dan boleh 
mempengaruhi hasil rawatan radioiodin. Walaubagaimanapun, tiada garis panduan khusus 
berkaitan amalan pemakanan untuk penyakit bukan barah tiroid, kaedah semasa yang 
diamalkan di kebanyakan pusat perubatan nuklear di Malaysia adalah untuk menasihati 
pesakit agar mengamalkan pemakanan diet sekatan iodin selama satu minggu untuk pesakit 
hipertiroid berbanding dua minggu untuk pesakit kanser tiroid. 
 
  
Objektif: Tujuan kajian ini adalah untuk menilai kesan amalan pemakanan diet sekatan iodin 
selama satu minggu berbanding dua minggu terhadap paras serum hormon perangsangan 
tiroid (thyroid stimulating hormone, TSH) dan hormon tiroksin bebas (free thyroxine, T4) 
selepas rawatan radioiodin serta kesan keberhasilan rawatan tersebut. 
 
Kaedah: Pesakit hipertiroid yang dirujuk untuk pertama kali menjalani rawatan radioiodin 
dibahagikan secara rawak kepada dua kumpulan mengikut tempoh amalan pemakanan diet 
sekatan iodin selama satu minggu atau dua minggu. Terdapat sejumlah 83 orang pesakit yang 
terlibat (n=44 dalam kumpulan satu minggu, n=39 dalam kumpulan dua minggu). Ujian air 
kencing untuk paras iodin yang diambil sebelum rawatan telah digunakan untuk menilai 
kepatuhan pesakit terhadap amalan pemakanan tersebut. Hasil rawatan yang diingini adalah 
x 
 
fungsi tiroid normal atau hipotiroid pada bulan ke-9 setelah rawatan. Data demografik dan 
klinikal pesakit telah dikumpulkan dan dianalisa. 
 
Keputusan: Kebanyakan pesakit adalah perempuan dengan purata umur 42 tahun dan 
memiliki kebengkakan kelenjar tiroid bedasarkan pemeriksaan klinikal. Pada rawatan susulan 
bulan ke-9, kebanyakan pesakit (83%) mencapai status tiroid yang diingini (fungsi tiroid 
normal atau hipotiroid). Tiada perkaitan signifikan yang dapat diperolehi di antara tempoh 
amalan pemakanan dengan nilai purata T4 (p=0.057) dan serum TSH (p=0.746) serta 
keberhasilan rawatan tersebut (p=0.294). Walaubagaimanapun, pesakit lelaki adalah 6.22 kali 
ganda berkemungkinan untuk memperolehi hasil rawatan yang tidak diingini (hipertiroid) 
berbanding peaskit wanita dan pertambahan paras iodin dalam air kencing sebelum rawatan 
adalah berkait dengan pertambahan kemungkinan untuk memperolehi hasil rawatan yang 
tidak diingini (hipertiroid).   
 
Kesimpulan: Tiada perbezaan yang signifikan di antara kesan amalan pemakanan diet 
sekatan iodin selama satu minggu berbanding dua minggu terhadap keberhasilan rawatan 
radioiodin. Walaupun secara umumnya tempoh satu minggu amalan pemakanan diet sekatan 
iodin didapati adalah mencukupi sebagai persediaan pesakit hipertiroid, usaha untuk 
memastikan kepatuhan dalam mengamalkan diet sekatan iodin sebelum rawatan boleh 
mempengaruhi kemujaraban rawatan radioiodin. Kajian pada masa akan datang dengan 
jumlah sampel yang lebih besar dan meliputi faktor-faktor penyumbang yang lain patut 
diteruskan bagi mendapatkan keputusan yang mungkin lebih relevan.             
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ABSTRACT 
 
Introduction: Therapy using radioactive Iodine-131 is an established method of treatment 
for thyroid diseases including hyperthyroidism related benign disorders as well as thyroid 
cancers. Pre-treatment dietary restriction to induce a state of iodine deficiency is considered 
important and may influence the radioiodine therapy outcome. Although there are no specific 
guidelines of dietary preparation for benign thyroid disorders, the current practice in most 
nuclear medicine centres in Malaysia is to advice one-week dietary restriction for 
hyperthyroidism patients as compared to two-week duration for thyroid cancer patients. 
 
Objective: The aim of this study is to evaluate the effect of one-week against two-week 
iodine restricted diet on the post radioiodine therapy levels of serum thyroid stimulating 
hormone (TSH) and free thyroxine (T4) levels as well as the treatment outcome. 
 
Methods: Hyperthyroidism patients referred for first radioiodine therapy were randomised 
into two groups according to one-week or two-week dietary restriction. There were 83 
patients (n=44 in one-week dietary restriction group, n=39 in two-week group). Pre-therapy 
urinary iodine test was done to document compliance towards the dietary restriction. 
Favourable therapy outcome includes euthyroid or hypothyroidism at 9 months post therapy. 
Demographic and clinical data were collected and analysed.  
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Results: Majority of the patients were females with mean age of 42 years old and had goitre 
clinically. At 9th month follow-up, majority of patients (83%) achieved favourable thyroid 
status. No significant statistical association was found between the duration of dietary 
restriction with mean free T4 (p=0.057) and serum TSH (p=0.746) levels as well as therapy 
outcome (p=0.294). However, male patients were 6.22 times more likely to develop 
unfavourable post therapy outcome compared to female patients and an increasing level of 
pre-treatment urinary iodine was associated with increased likelihood of developing 
unfavourable post therapy outcome.           
 
Conclusion: There is no significant difference between the effects of one-week against two-
week iodine restricted diet on the post radioiodine therapy outcome. Although generally a 
period of one-week iodine restriction appears to be adequate for the preparation of 
hyperthyroidism patients, efforts to ensure adequate compliance and stringency should be 
advocated as these may possibly influence the efficacy of dietary restriction and radioiodine 
therapy. Future studies with larger sample size and covering other contributing factors are 
recommended. 
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1.1 Introduction 
Benign disorders of the thyroid gland usually present with alteration in the thyroid 
function and may well be accompanied by goitre or thyroid swelling. In general, the state of 
excessive thyroid hormones or thyrotoxicosis is caused by various aetiologies such as 
Graves’ disease, thyroiditis, factitious thyroxine intake and struma ovarii, while 
hyperthyroidism commonly relates to a hyper-functioning thyroid gland. Nevertheless, both 
terms (i.e. hyperthyroidism and thyrotoxicosis) are interchangeably used (Topliss et al., 
2004).  
There are no official statistics available on the prevalence of hyperthyroidism in 
Malaysia. However, the prevalence of hyperthyroidism in neighbouring Indonesia is reported 
to be about 6.9% (Indonesian Society of Endocrinology, 2012). In the United Kingdom, 
prevalence of hyperthyroidism among women is 2% while among men is 0.2% (Collier, 
2012). The most common causes of hyperthyroidism in the United States are Graves’ disease, 
toxic multinodular goitre (MNG) and toxic adenoma (Bahn et al., 2011). In Australia, 
similarly Graves’ disease and toxic MNG are the most common causes of hyperthyroidism 
(Topliss et al., 2004). Graves’ disease has been estimated to affect approximately 0.5% of the 
general population, predominantly female in the age group of 40 to 60 years old (Abraham 
and Acharya, 2010). The prevalence of toxic MNG increases with age and in regions of 
iodine deficiency (Zainudin et al., 2012).         
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1.2 Brief Anatomy and Physiology of Thyroid 
The thyroid gland is an essential organ and fundamental component of the complex 
human endocrine system. It has the ability to concentrate iodide from dietary iodine in order 
to produce the thyroid hormones. Apart from significant role in the regulation of protein and 
carbohydrate metabolisms, these thyroid hormones have important effects on our growth as 
well as the cardiovascular, respiratory and sympathetic nervous systems.  
 
Figure 1.0: Anterior view of the thyroid gland (adapted from Medscape.com, accessed on 1/10/2015) 
The thyroid gland consists of right lobe and left lobe connected by isthmus. It is 
located in the lower neck just below the thyroid cartilage at the anterior superior aspect of the 
trachea. The arterial supply of the gland is from the superior thyroid artery which is a branch 
of the external carotid artery and inferior thyroid artery which is a branch of the thyrocervical 
trunk. The venous drainage of the thyroid gland is by the superior, middle and inferior 
thyroid veins. The gland is supplied by both parasympathetic and sympathetic nerves. 
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The average weight of the thyroid gland is approximately 15-20 grams (Ziessman, 
O’Malley and Thrall, 2006). A cross-sectional postmortem study conducted in a South-Asian 
country reported that the mean weight of the thyroid gland for middle aged females and 
males to be approximately 19 grams (Nurrunabi et al, 2010). Microscopically the thyroid 
gland is comprised of numerous follicles of varying sizes that are enclosing colloid-filled 
cavities or follicular lumens (Figure 2.0).  
         
Figure 2.0: Thyroid follicles (adapted from Medscape.com, accessed on 1/10/2015) 
After oral consumption, dietary iodine from food is promptly reduced to iodide in the 
upper small intestine and being distributed in the blood as an extracellular ion similar to 
chloride (Ziessman, O’Malley and Thrall, 2006). Iodide is subsequently trapped by the 
thyroid follicular cell through a high-energy carrier mediated sodium iodide thyroid pump 
before being converted into thyroid hormones through a series of metabolic steps (Ivanac et 
al., 2004). In the normal thyroid gland, synthesis of thyroid hormones through oxidation and 
organification process promptly follows trapping of iodide (Ziessman, O’Malley and Thrall, 
2006).  
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The biosynthesis and secretion of thyroid hormones into the circulation are stimulated 
by the thyroid stimulating hormone (TSH) and inhibited by excess iodine (Cavalieri, 1997). 
The TSH secretion on the other hand is being principally regulated by the thyroid-pituitary 
feedback mechanism which is very sensitive to circulating serum thyroid hormone levels. 
The main thyroid hormone released by the thyroid gland is thyroxine (T4) which then being 
transported to peripheral tissues by thyroid binding proteins and finally converted to the more 
metabolically active triiodothyronine (T3) at the site of action (Ziessman, O’Malley and 
Thrall, 2006).  
 
1.3  Management of Hyperthyroidism  
Patients with hyperthyroidism may be asymptomatic but commonly present with 
substantial symptoms. They may experience symptoms of irritability, nervousness, 
palpitation, excessive sweating, heat intolerance, hand tremors and weight loss in spite of 
good appetite. Examples of signs of thyrotoxicosis are tachycardia, atrial fibrillation, fine 
tremor and goitre (Iagaru and McDougall, 2007). Patients may also present with any of the 
associated complications. Common complications include hypokalaemic periodic paralysis, 
pretibial myxoedema, thyroid cardiomyopathy and Graves’ opthalmopathy (Zainudin et al., 
2012). Institutional studies in Malaysia showed the prevalence of thyroid associated 
opthalmopathy among Graves’ disease patients was approximately 34.7% (Lim et al, 2008), 
while hypokalaemic periodic paralysis were present in 5.0% of the cases (Tan et al, 1989).   
Confirmatory diagnosis of hyperthyroidism is usually done by laboratory 
measurement of the serum TSH and free T4. In fact the diagnostic accuracy improves when 
both parameters are evaluated particularly when hyperthyroidism is strongly suspected (Bahn 
et al., 2011). Measuring free T4 is preferred compared to total T4 as measurement of total T4 
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is affected by protein binding abnormalities (Zainudin et al., 2012). However, in patients with 
low TSH but normal free T4 such as in early stage of the disease or autonomously functioning 
thyroid nodule, only the serum T3 level may be elevated and hence should be measured (Bahn 
et al., 2011).   
Additional laboratory test to detect thyrotropin receptor antibodies (TRAb) is 
particularly useful in diagnosing Graves’ disease as it is a sensitive marker of the disease. 
Other relevant investigations that would be helpful in the evaluation of thyrotoxicosis are 
radioiodine uptake study (RAIU) and radionuclide thyroid scan (Bahn et al., 2011, Zainudin 
et al., 2012). In our local setting, ultrasonography of the thyroid gland is also occasionally 
being performed in addition to the stated laboratory tests as part of the disease assessment. 
Thyroid ultrasound remains a valuable tool in the evaluation of thyroid disorders including 
estimation of thyroid volume and characterization of palpable nodules as well as in 
sonographic guided fine needle aspiration biopsy (Tessler and Tublin, 1999). 
Generally the treatment options available for hyperthyroidism consist of anti-thyroid 
drugs, surgery and radioiodine therapy. In the local setting, majority of patients are treated 
with thionamide anti-thyroid drugs up to 18 months before being tapered off. Hong et al. 
(2007) described that in Malaysia the most consumed thionamide was carbimazole (82.8%) 
followed by propylthiouracil (17.2%). The consumption of anti-thyroid drugs was reported to 
be higher locally compared to Australia which might possibly related to the local preference 
for drugs as the first-line therapy while radioiodine which is available only in several regional 
centres being typically placed as the second-line therapy (Hong et al, 2007). Prolonged usage 
of thionamides may cause minor and transient adverse effects such as skin rash, itchiness and 
mild leucopenia. However, the most dangerous side effect is agranulocytosis which can occur 
in approximately 0.5% of the patients (Bartalena, Bogazzi and Martino, 1996). As for surgery 
in hyperthyroidism, it is indicated for cases of goitre with pressure effects, suspected thyroid 
7 
 
malignancy, severe progressive opthalmopathy or when medical therapy fails (Zainudin et al, 
2012).  
 
1.4 Radioiodine Therapy  
The oral administration of I-131 has been generally a well-recognised procedure in 
treating both benign and malignant disorders of the thyroid for the last 70 years (Silberstein et 
al., 2012). Examples of the common clinical indications for radioiodine therapy are Graves’ 
disease, toxic nodular thyroid diseases and well differentiated thyroid cancers such as 
papillary and follicular carcinoma. Absolute contraindications for I-131 therapy include 
pregnancy and breastfeeding (Stokkel et al, 2010, Sisson et al., 2011). The use of radioiodine 
in treating hyperthyroidism is substantially more frequent in the United States compared to 
Europe and parts of Asia (Abraham and Acharya, 2010). 
Both Society of Nuclear Medicine and European Association of Nuclear Medicine 
guidelines defined I-131 as a β-emitting radionuclide with a physical half-life of 
approximately 8 days with a principal γ-ray of 364 KeV and a principal β-particle with a 
maximum energy of 0.61 MeV, an average energy of 0.192 MeV, and a range in tissue of 0.4 
mm (Silberstein et al, 2012, Stokkel et al, 2010). The thyroid gland receives the highest 
radiation absorbed dose. Assuming 55% thyroid uptake in a 20 gram of hyperthyroid gland, 
the calculated radiation absorbed dose is 790 mGy/MBq to the thyroid gland followed by 
0.290 mGy/MBq to urinary bladder wall and less than 0.1 mGy/MBq to other organs 
(Silberstein et al., 2012).  
The basis of radioiodine therapy is physiological whereby I-131 is taken up by iodide 
transporter of the thyroid gland and processed the same way as natural iodine. Subsequently 
β-particles from I-131 will deliver ionising radiation that disrupts chemical bonds throughout 
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the thyroid cells, inflicting devastating damage on DNA molecules and triggering cellular 
dysfunction causing ultimately cell death (Robbins and Schlumberger, 2005). These will lead 
to thyroid volume decrease and control of thyrotoxicosis (Mumtaz et al., 2009).  
The reason for I-131 therapy among patients who had received anti-thyroid drugs was 
either because of failure of medical treatment (70%) or disease recurrence (11%) as reported 
in a retrospective study involving 258 patients (Sztal-Mazer et al., 2012). Around 50–90% of 
hyperthyroid patients are cured within one year following I-131 therapy (Bonnema and 
Hegedus, 2012). The goal of radioiodine therapy for hyperthyroidism is to achieve a non-
hyperthyroid status either a euthyroid state or iatrogenic hypothyroidism that should be 
adequately compensated with oral levothyroxine (Silberstein et al., 2012). Thus, 
hypothyroidism post radioiodine therapy is commonly accepted to be a favourable outcome 
and should subsequently be treated with levothyroxine. Several studies have defined 
hypothyroidism following I-131 administration as low free T4 with high TSH requiring 
thyroxine hormone replacement whereas euthyroid as normal thyroid function off all thyroid 
medication and hyperthyroidism requiring further radioiodine as a relapsing high free T4 and 
suppressed TSH at one year post therapy (Lewis et al., 2013, Yau et al., 2009).  
In general, the treatment with radioactive I-131 for hyperthyroidism has minimal 
adverse effects. Transient exacerbation of hyperthyroid symptoms due to radiation thyroiditis 
may occur 1–2 weeks after therapy (Mumtaz et al., 2009). However, these symptoms would 
usually respond to short-term beta blocker therapy if required. Thyroid ophthalmopathy may 
worsen or develop after I-131 therapy for Graves’ disease, especially among patients who are 
smokers (Silberstein et al., 2012).  It has been suggested by several studies that these patients 
should be covered with steroids (Mumtaz et al., 2009). Society of Nuclear Medicine has 
highlighted that based on previous multicenter trials; there is no evidence of an increased risk 
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of thyroid carcinoma or other cancers following radioiodine therapy for hyperthyroidism 
(Silberstein et al., 2012).   
Widely deployed methods for determining the dose of I-131 activity for radioiodine 
therapy of hyperthyroidism are by prescribing (a) ﬁxed empirical dose for all patients, (b) 
dose corrected for thyroid size and iodine uptake study and (c) quantity of I-131 calculated to 
deliver a specific radiation dosimetry to the thyroid gland (Kalinyak and McDougall, 2003). 
Nevertheless, there are no advantages that could be proven in using adjusted dose method as 
well as no differences in the time to outcome between the fixed and adjusted dose methods 
(Leslie et al., 2003). Similarly, Jaiswal et al. (2014) reported that there was no statistically 
significant difference between the success rates of the two methods at 3 months post therapy 
among Graves’ disease patients in India. A fixed dose regime has been suggested to be 
simple, more convenient to use and effective to achieve treatment goals (Mumtaz et al., 2009, 
Yau et al., 2009).   
Fixed doses of radioiodine activity for hyperthyroidism are commonly in the range of 
185–555 MBq (5–15 mCi) which enable additional incremental dose of I-131 when the gland 
is large (Iagary and McDougall, 2007). Good therapy outcome was seen following 
administration of doses less than 370 MBq (10 mCi) for normal sized thyroid glands and 
approximately 555 MBq (15 mCi) for large thyroid glands (Shinto, Pachen and Sreekanth, 
2010). Lewis et al. (2013) reported that a single standard dose of 550 MBq (14.9 mCi) to be 
highly effective in treating hyperthyroidism in a study that includes Graves’ disease and toxic 
MNG.  
In addition to the dosage of I-131, a number of parameters could influence the effect 
and outcome of radioiodine therapy. These include age and gender of the patients, thyroid 
size, severity of the disease and usage of anti-thyroid medications. Nevertheless, based on 
current knowledge, it appears clear that no single factor reliably predicts the outcome of 
10 
 
radioiodine therapy and these factors probably interact mutually in a complex manner 
(Bonnema and Hegedus, 2012).           
 
1.5 Radioiodine Therapy in Malaysia 
At present, the therapy with I-131 for thyroid diseases has become one of the main 
therapeutic services available in Malaysian government hospitals and institutions with 
nuclear medicine facilities. Locally most of the nuclear medicine centres prescribe a fixed 
dose of radioiodine with consideration given to the thyroid size made on clinical palpation 
and assessment (Zanial and Hamzah, 2015). A Summary of Consensus for the Management 
of Thyroid Disorders in Malaysia has recommended a fixed dose of 370–555 MBq (10–15 
mCi) (Zainudin et al., 2012).  
 
1.6 Patient Preparation and Iodine Restricted Diet 
Generally a state of iodine deficiency should be induced in order to subsequently 
increase the I-131 uptake (Silberstein et al., 2012). Hence, as part of the preparation 
measures, patients are advised to avoid and stop consuming anti-thyroid drugs for 1–2 weeks, 
iodine containing substance such as expectorants, agar and Lugol’s iodine for 2–3 weeks, 
multivitamin for 7 days, amiodarone for 3–6 months or longer and radiographic contrast 
agents for 3–4 weeks prior to radioiodine therapy and should be placed on an iodine restricted 
diet (Mumtaz et al., 2009).   
Among patients with well differentiated thyroid cancer, a temporary low-iodine diet is 
recommended before they undergo I-131 treatment (Sawka et al., 2010, Li et al., 2015). In the 
United States, a low iodine diet with intake less than 50 µg of iodine per day for 1–2 weeks 
11 
 
before radioiodine ablation is recommended by the American Thyroid Association (Cooper et 
al., 2009).  Based on available data, majority of the population in the United States are iodine 
sufficient (Li et al., 2015). The rationale for low iodine diet in such circumstances is it would 
help to deplete iodine concentration in the body and optimise radioiodine uptake in the 
thyroid cells (Sawka et al., 2010).  
Patients being prescribed with low iodine diet are required to avoid foods which are 
rich in iodine (Park and Hennessey, 2004, Tamoda et al., 2005). Dietary sources with highest 
iodine content are marine products such as fish, shellfish and seaweed followed by egg, milk, 
dairy products and fortified or iodised salt (European Food Safety Authority, 2014). Other 
examples of food with high iodine contents are breads made with iodinated dough 
conditioners, chocolate as well as dried and cured food products (Park and Hennessey, 2004). 
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2.1  Problem Statement and Rationale of Study  
A systemic review on dietary iodine restriction prior to I-131 treatment or scanning in 
well differentiated thyroid cancer had advocated the use of low iodine diet for the duration of 
up to two weeks as part of the preparation measures (Sawka et al., 2010). In contrast, the 
duration of dietary iodine restriction is unclear for benign thyroid diseases although the 
recommendation for thyroid cancer patients may be as long as 10-14 days (Mumtaz et al, 
2009). A review article by Lee (2012) has suggested a simplified low-iodine diet for 5-7 days 
among hyperthyroidism patients. Nevertheless, at present there is no randomised study or 
standardised guideline on the timing of dietary restriction for hyperthyroidism patients 
undergoing radioiodine therapy. Society of Nuclear Medicine, United States and its 
counterpart the European Association of Nuclear Medicine in their respective latest practice 
guidelines did not specify any duration for iodine restricted diet for benign thyroid diseases 
(Silberstein et al., 2012, Stokkel et al, 2010).  
The current practice in Malaysia including Hospital Pulau Pinang is to advice for one-
week iodine restricted diet among hyperthyroidism patients and two-week iodine restricted 
diet among thyroid cancer patients. Although stringency is not usually specified, the 
emphasis is placed on the avoidance of iodine containing food, seafood including fish, 
shellfish, prawn and squid, kelp and supplements that contain high iodine and iodized salt 
(Zanial and Hamzah, 2015). For thyroid cancer, the duration of low iodine diet is a crucial 
factor as iodine intake can vary by geographic region as well as individual's dietary 
preferences and in areas where the average estimated iodine intake is high, individuals may 
require a longer length of iodine restriction (Li et al., 2015). Likewise for hyperthyroidism, 
the one-week restriction may not be adequate for some patients with probable high dietary 
iodine consumption. Longer duration of iodine restricted diet is thought to enhance the state 
of iodine deficiency and subsequently promote better I-131 uptake by the thyroid gland 
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contributing towards favourable treatment outcome. Therefore, the aim of this present study 
was to determine the most appropriate timing of dietary iodine restriction as part of the pre-
treatment preparation among hyperthyroidism patients that would eventually result in a 
favourable post therapy thyroid status.  
 
2.2 Objectives of Study  
 
2.2.1 General Objective 
The primary objective is to evaluate the impact of one-week against two-week iodine 
restricted diet has on the post radioiodine therapy outcome (i.e. euthyroid, hypothyroid or 
hyperthyroid status biochemically) among hyperthyroidism patients undergoing first 
radioiodine therapy. 
 
2.2.2 Specific Objectives 
There are three specific objectives for this study; 
i. To evaluate the TSH and free T4 levels based on the thyroid function test (TFT) of 
these patients at 6th and 9th month post therapy. 
ii. To determine the post therapy thyroid status biochemically (i.e. euthyroid, 
hypothyroidism or hyperthyroidism) based on the TFT values at 9th month post 
therapy.   
iii. To correlate the impact of iodine restricted diet on post therapy TFT levels and the 
thyroid status at 9th month post therapy. 
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2.3 Research hypotheses 
The null hypothesis for this study is that there is no significant difference between the 
impact of one-week and two-week iodine restricted diet on the post radioiodine therapy 
outcome amongst hyperthyroidism patients. The alternative hypothesis is that the two-week 
iodine restricted diet has a better impact (i.e. favourable biochemical status) compared to the 
one-week diet on the post radioiodine therapy outcome amongst hyperthyroidism patients. 
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METHODS 
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3.1  STUDY BACKGROUND, DESIGN AND PERIOD 
This was a randomised prospective study that was conducted in Hospital Pulau 
Pinang. It involved hyperthyroidism patients undergoing first radioiodine therapy at the 
Nuclear Medicine Department, Hospital Pulau Pinang which was one of the regional nuclear 
medicine centres under the jurisdiction of Ministry of Health Malaysia. Presently, Hospital 
Pulau Pinang is the main referral centre for the northern region of Peninsular Malaysia 
covering the states of Perlis, Kedah, Penang and northern Perak (Appendix F). 
 
3.1.1  Study Period 
The total study period was 17 months beginning from 1st February 2014 until 30th 
June 2015. The sampling frame for patient recruitment was from 1st February 2014 until 30th 
September 2014. Enrolled patients were being follow-up for duration of 9 months and the last 
review session was on 30th June 2015. 
 
3.2   STUDY POPULATION AND SAMPLE SIZE 
The sampling population of this study was derived from all hyperthyroidism patients 
referred from within and outside Hospital Pulau Pinang for first radioiodine therapy. The 
sample size was calculated using PS Power and Sample Size Ver.3.0.10, 2009 (Appendix B). 
The required size to achieve a power of 70% and confidence interval of 95% was 101 
patients. Therefore, the needed sample size for this study was 111 patients considering 
dropout rate of 10%. The calculation was based on 25% difference of a previous study 
produced by Morris et al. with standard deviation 127.7 (Morris et al., 2001). Although that 
study was conducted among thyroid cancer patients, it was chosen as a reference for sample 
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size calculation as there was no published similar study being done among hyperthyroidism 
patients prior to the initiation of this study.  
 
3.2.1  Sampling procedure   
The total number of patients recruited for this study based on the selection criteria 
were 83 patients (74.8% of the calculated sample size). Patients had been randomised and 
assigned into two groups using opaque-sealed envelopes containing computer generated 
randomisation numbers. The first group (44 patients) underwent one-week dietary restriction 
and the second group (39 patients) underwent two-week dietary restriction.  
 
3.3 SELECTION CRITERIA 
3.3.1 Inclusion Criteria:  
• Patients undergoing first radioiodine ablation 
• Patients aged between 18 years old and 65 years old  
 
3.3.2  Exclusion Criteria:  
• Patients with hyperthyroidism associated opthalmopathy 
• Patients who are pregnant or breastfeeding 
• Patients who have underwent recent (within 1 month) contrasted radiographic study  
• Patients who have underwent previous thyroid surgery 
• Patients who lost to follow up post radioiodine therapy   
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3.4  MINIMIZING SAMPLING ERROR 
Data collection was performed by primary/principal investigator. 
 
3.5  ETHICAL BOARD 
This study has been registered with the National Medical Research Register (NMRR) 
of Malaysia. The protocol for this study was submitted to the Medical Research Ethics 
Committee (MREC) of the Ministry of Health Malaysia and has been approved by the 
committee (Appendix C). The study protocol was also reviewed and approved by the 
Research Secretariat of Advanced Medical and Dental Institute, Universiti Sains Malaysia 
and Research Ethics Committee (Human) of Universiti Sains Malaysia. 
 
3.6  METHODOLOGY 
The current practice in the Department of Nuclear Medicine, Hospital Pulau Pinang is 
to prescribe fixed dose of 555 MBq (15 mCi) for all hyperthyroidism cases referred for 
radioiodine therapy. Liquid I-131 is administered orally to patients as an outpatient 
procedure. In conjunction with local regulations, the radiation exposure rate has been 
calculated to be equivalent to or less than the permissible value of 6.6 mR/hour measured at 
one meter distance. Patients are required to attend scheduled clinic follow up sessions every 3 
months for 1 year duration at the Nuclear Medicine Department, Hospital Pulau Pinang. At 
each session, patients are being assessed clinically on their signs and symptoms pertaining to 
the thyroid status and respond towards therapy apart from biochemical monitoring of the free 
T4 and TSH levels taken prior to the follow up session. Patients with favourable thyroid status 
either biochemically euthyroid or hypothyroidism at approximately one year post therapy will 
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be considered as successfully treated with radioiodine. Hypothyroidism patients will be 
placed on life-long thyroxine hormone replacement. However, patients who are still 
hyperthyroid will be advised for another low dose radioiodine therapy. 
 
3.6.1  Patient Preparations and Iodine Restricted Diet  
Patient preparation will help in ensuring the effectiveness of radioiodine therapy. 
Briefing session and dissemination of transcribed information on the pre-treatment 
preparation as well as the therapy procedure are well recommended measures (Royal College 
of Physicians, 2007, Stokkel et al., 2010, Silberstein et al., 2012). After being randomised and 
assigned to their respective dietary group, patients were given pre-therapy counselling and 
briefing conducted by medical officers in the Nuclear Medicine Department, Hospital Pulau 
Pinang. A copy of the formal written departmental leaflet on the instruction and preparation 
list for low dose radioiodine therapy was also provided to the referring team and handed over 
to the patients.  
Patients were instructed to stop consuming anti-thyroid drug such as carbimazole and 
propylthiouracil for 7 days prior to radioiodine therapy and should only resume taking the 
medication after 7 days following the therapy. Patients were ensured not to be on medication 
containing high-iodine such as amiodarone apart from having no recent history of contrasted 
radiographic examination. They were also advised to avoid iodine containing food and stop 
consuming seafood, kelp, supplements or multivitamins that contain high iodine and iodized 
salt for 7 or 14 days depending on their randomised dietary group. They were given a simple 
structured dietary recommendation and instruction tailored to local food intake prepared by 
the hospital dietician (Appendix D). Referral for dietician consultation was offered and aided 
